Thomas E. Witzig
Mayo Clinic
781 Papers
5.5K Citations
Thomas E. Witzig is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Diffuse large B-cell lymphoma. The author has an hindex of 115, co-authored 706 publications. Previous affiliations of Thomas E. Witzig include ZymoGenetics & University of Iowa.
Chat about Author
Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu,Frederick L. Locke,Nancy L. Bartlett,Lazaros J. Lekakis,David B. Miklos,Caron A. Jacobson,Ira Braunschweig,Olalekan O. Oluwole,Tanya Siddiqi,Yi Lin,John M. Timmerman,Patrick J. Stiff,Jonathan W. Friedberg,Ian W. Flinn,Andre Goy,Brian T. Hill,Mitchell R. Smith,Abhinav Deol,Umar Farooq,Peter A. McSweeney,Javier Munoz,Irit Avivi,Januario E. Castro,Jason R. Westin,Julio C. Chavez,Armin Ghobadi,Krishna V. Komanduri,Ronald Levy,Eric D. Jacobsen,Thomas E. Witzig,Patrick M. Reagan,Adrian Bot,John J. Rossi,Lynn Navale,Yizhou Jiang,Jeff Aycock,Meg Elias,David Z. Chang,Jeff Wiezorek,William Y. Go +39 more
TL;DR: Patients with refractory large B‐cell lymphoma who received CAR T‐cell therapy with axi‐cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events.
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Robert A. Kyle,Morie A. Gertz,Thomas E. Witzig,John A. Lust,Martha Q. Lacy,Angela Dispenzieri,Rafael Fonseca,S. Vincent Rajkumar,Janice R. Offord,Dirk R. Larson,Matthew E. Plevak,Terry M. Therneau,Philip R. Greipp +12 more
- 01 Jan 2003
TL;DR: Multivariate analysis revealed that age, plasma cell labeling index, low platelet count, serum albumin value, and the log of the creatinine value were the most important prognostic factors for newly diagnosed multiple myeloma.
2.4K
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
Thomas E. Witzig,Leo I. Gordon,Fernando Cabanillas,Myron S. Czuczman,Christos Emmanouilides,Robin Joyce,Brad Pohlman,Nancy L. Bartlett,Gregory A. Wiseman,Norman Padre,Antonio J. Grillo-Lopez,Pratik S. Multani,Christine A. White +12 more
TL;DR: Radioimmunotherapy with (90)Y ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher ORR and CR compared with rituximab alone.
1.2K
International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease
Arezou Khosroshahi,Zachary S. Wallace,J. L. Crowe,Takashi Akamizu,Atsushi Azumi,M. N. Carruthers,Suresh T. Chari,Emanuel Della-Torre,Luca Frulloni,Hiroshi Goto,Phil A. Hart,Terumi Kamisawa,Shigeyuki Kawa,Mitsuhiro Kawano,Myung-Hwan Kim,Yuzo Kodama,Kensuke Kubota,Markus M. Lerch,Matthias Löhr,Yasufumi Masaki,Shoko Matsui,Tsuneyo Mimori,Seiji Nakamura,Takahiro Nakazawa,Hirotaka Ohara,Kazuichi Okazaki,Jay H. Ryu,Takako Saeki,Nicolas Schleinitz,Akira Shimatsu,Toru Shimosegawa,Hiroki Takahashi,Masayuki Takahira,Atsushi Tanaka,Mark Topazian,Hisanori Umehara,George J. Webster,Thomas E. Witzig,Motohisa Yamamoto,W. Zhang,Tsutomu Chiba,John H. Stone +41 more
TL;DR: A. H. Wallace, J. L. Carruthers, S. L€ ohr, Y. Khosroshahi, Z. Chari, E. Della-Torre, L. Frulloni, H.
956
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
Angela Dispenzieri,Morie A. Gertz,Robert A. Kyle,Martha Q. Lacy,Mary F. Burritt,Terry M. Therneau,Philip R. Greipp,Thomas E. Witzig,John A. Lust,S. Vincent Rajkumar,Rafael Fonseca,Steven R. Zeldenrust,Christopher G.A. McGregor,Allan S. Jaffe +13 more
TL;DR: Stratification of AL patients into three stages is possible with two readily available and reproducible tests setting the stage for more consistent and reliable cross comparisons of therapeutic outcomes.
900